Unfair deal for German outpatients in 2000
This article was originally published in Clinica
Doctors in neither the former West Germany nor East Germany can be pleased at the financial development of the statutory sickness funds during the last year, asserts Dr Manfred Richter-Reichhelm, principal chairman of the national association of statutory health insurance physicians (KBV).
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.